Carling L, Cronstedt J, Engqvist A, Kagevi I, Nyström B, Svedberg L E, Thorhallsson E, Unge P, Wingren P E
Dept. of Medicine, Bollnäs Hospital Sweden.
Scand J Gastroenterol. 1988 Nov;23(9):1117-24. doi: 10.3109/00365528809090178.
The healing capacity and symptom relief were studied in 138 patients with symptomatic endoscopically verified reflux esophagitis treated with sucralfate (n = 69) or placebo (n = 69), 1 g four times daily (granules suspended in half a glass of water), for at most up to 12 weeks. The reflux esophagitis (modified Savary-Miller scale) was distributed with 71 patients having grade 1, 39 patients having grade 2 or 3, and 28 patients having grade 4. All patients were told to follow the antireflux regimen. Antacid tablets were supplied, to be used only for the relief of severe pain, and were counted. The esophageal lesions were completely healed in 42% (sucralfate) and 35% (placebo) after 6 weeks of treatment (NS). Corresponding cumulative healing rates at 12 weeks of treatment were 54% and 41% (NS), respectively. The symptom improvement, however, was significantly better in the sucralfate group after 3 weeks of treatment. The results indicate a symptomatic benefit of sucralfate in reflux esophagitis.
对138例经内镜检查证实有症状的反流性食管炎患者进行了愈合能力和症状缓解情况的研究，这些患者分别接受硫糖铝（n = 69）或安慰剂（n = 69）治疗，每日4次，每次1 g（颗粒剂溶于半杯水），最长治疗12周。反流性食管炎（改良Savary-Miller量表）分级情况为：71例为1级，39例为2级或3级，28例为4级。所有患者均被告知遵循抗反流治疗方案。提供了抗酸片，仅用于缓解剧痛，并对其使用情况进行了计数。治疗6周后，硫糖铝组和安慰剂组食管病变的完全愈合率分别为42%和35%（无显著性差异）。治疗12周时相应的累积愈合率分别为54%和41%（无显著性差异）。然而，治疗3周后硫糖铝组的症状改善明显更好。结果表明硫糖铝对反流性食管炎有症状改善作用。
